Method and composition for inhibiting EGF / EGFR pathway in combination with tyrosine kinase inhibitor

摘要

The present invention relates to a method for the treatment of dendritic human epidermis comprising administering to a patient in need of such treatment a flexible active regimen combining a tyrosine kinase inhibitor (TKI) and an anti-EGF antibody for inhibiting the pathway activated by EGF-EGFR binding (mAb) A method of treating a cancer patient induced by a proliferative factor receptor (HER1 / human EGFR). Anti-EGF antibodies can be provided passively by administration of antibodies that are anti-EGF or by active immunization. The method comprises administering a TKI according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg, wherein the mAb is administered three times per week, twice or once, every two weeks, once every three weeks Or either active or passive, depending on the dosing regimen achieving a therapeutically effective dose repeatedly at least once a month.